(Q50127828)

25 February 2018

title

Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study (English)

1 reference

25 February 2018

0 references

S Minden

1

1 reference

25 February 2018

D Hoaglin

2

1 reference

25 February 2018

S Jureidini

3

1 reference

25 February 2018

L Hadden

4

1 reference

25 February 2018

D Frankel

5

1 reference

25 February 2018

Y Komatsuzaki

6

1 reference

25 February 2018

J Outley

7

1 reference

25 February 2018

publication date

1 June 2008

1 reference

25 February 2018

Multiple Sclerosis Journal

published in

1 reference

25 February 2018

volume

14

1 reference

25 February 2018

issue

5

1 reference

25 February 2018

page(s)

640-655

1 reference

25 February 2018

Interferon-alpha2a reduces MRI disease activity in relapsing-remitting multiple sclerosis. Norwegian Study Group on Interferon-alpha in Multiple Sclerosis.

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458507086463

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507086463

International consensus statement on the use of disease-modifying agents in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507086463

Disease-modifying Therapies for Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507086463

Effect of drugs in secondary disease progression in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507086463

Treatment patterns of multiple sclerosis patients: a comparison of veterans and non-veterans using the NARCOMS registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507086463

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507086463

Twenty-four-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507086463

Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507086463

Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507086463

Immunomodulatory treatment of multiple sclerosis in denmark: a prospective nationwide survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507086463

Long-term interferon-beta treatment for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507086463

A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507086463

Long-term emotional state of multiple sclerosis patients treated with interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507086463

A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507086463

Lessons from 10 years of interferon beta-1b (Betaferon/Betaseron) treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507086463

Managing the adverse effects of interferon-beta therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507086463

Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507086463

Strategies for managing the side effects of treatments for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507086463

Factors leading patients to discontinue multiple sclerosis therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507086463

Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507086463

Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507086463

Course of depression during the initiation of interferon beta-1a treatment for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507086463

Multiple sclerosis: side effects of interferon beta therapy and their management

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507086463

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507086463

Defining the clinical course of multiple sclerosis: Results of an international survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507086463

Access to health care for people with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507086463

Axonal transection in the lesions of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507086463

Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507086463

Decisional role preferences, risk knowledge and information interests in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507086463

21 January 2018

Identifiers

DOI

10.1177/1352458507086463

1 reference

25 February 2018

1 reference

25 February 2018